PMC:7534795 / 45482-45766
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T207 | 148-158 | Body_part | denotes | fatty acid | http://purl.org/sig/ont/fma/fma82738 |
| T208 | 190-198 | Body_part | denotes | capsules | http://purl.org/sig/ont/fma/fma85272 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T336 | 164-167 | Disease | denotes | FFA | http://purl.obolibrary.org/obo/MONDO_0016776 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T357 | 107-109 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T359 | 121-142 | Chemical | denotes | Eicosapentaenoic acid | http://purl.obolibrary.org/obo/CHEBI_28364 |
| T360 | 138-142 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
| T361 | 148-158 | Chemical | denotes | fatty acid | http://purl.obolibrary.org/obo/CHEBI_35366 |
| T362 | 154-158 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
| T363 | 160-163 | Chemical | denotes | EPA | http://purl.obolibrary.org/obo/CHEBI_28364|http://purl.obolibrary.org/obo/CHEBI_36006 |
| T365 | 164-167 | Chemical | denotes | FFA | http://purl.obolibrary.org/obo/CHEBI_42638 |
| T366 | 263-273 | Chemical | denotes | Colchicine | http://purl.obolibrary.org/obo/CHEBI_27882 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T389 | 65-242 | Sentence | denotes | • Secondary outcome includes reduction of IL-6 levels • Eicosapentaenoic acid free fatty acid (EPA-FFA) 1 g gastro-resistant capsules twice daily (2 g total) (NCT04335032, 2020) |
| T390 | 243-260 | Sentence | denotes | • COLCORONA Trial |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1304 | 107-111 | Gene | denotes | IL-6 | Gene:3569 |